VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2020 | Daratumumab in the treatment of MM with high-risk cytogenetics

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the meta-analysis of randomized phase III trials of daratumumab in the treatment of multiple myeloma (MM) with high-risk cytogenetics. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter